drugset / Trial / NCT06216886

OnabotulinumtoxinA for Trigeminal Neuralgia

NCT06216886 ↗

Phase 4 Recruiting 20 enrolled Stanford University
RandomizedParallel-groupTriple-blindTreatment

Summary

A randomized controlled trial comparing Onabotulinumtoxin A to saline (placebo) for Trigeminal Neuralgia.

Timeline

Start
2024-06-01
Primary completion
2027-02-01
Completion
2027-09-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 25 unknown Intravenous
Subject Botulinum toxin type A Protein / enzyme biologic 50 unknown Intravenous
Subject Botulinum toxin type A Protein / enzyme biologic 75 unknown Intravenous

Indications